Industry News

The Swiss-based contract development and manufacturing organization wants to become a “pure-play” CDMO business, as part of a new strategy and organizational structure.

The agreement aims to enhance R&D, biomanufacturing, and training Saudi talent in biotechnology.

The Japanese pharma’s planned antibody-drug conjugate (ADC) manufacturing facility in Shanghai is part of its continuing investment in the growing cancer therapeutic class.

The teaming provides Cellipont with access to Xiogenix’s Ares X20 fill-and-finish system.

The Swiss biotech, focused on cell and gene therapy (CGT) production, has launched a new U.S. subsidiary.

The collaboration is intended to create a connected workflow for cell and gene therapy (CGT) manufacturing.

The Shanbally location is BioMarin’s only manufacturing site outside the U.S., which includes an aseptic production facility opened last year.

The integration brings 54 regional hubs across 26 countries and combines Tower’s reusable passive containers with CCT’s single-use packaging solutions.

China-based contract manufacturers targeted in the proposed legislation are off the hook, for now, as the likelihood of the measure being passed into law this year is slim.

While the buyout has secured EU approval, the U.S. Federal Trade Commission is still reviewing the proposed transaction.

The CDMO will provide Eli Lilly's biotechnology collaborators with access to its clinical development capabilities.

Construction is set to begin next year, adding 750 jobs to the current workforce of over 100 and supporting 2,000 construction roles.

The company’s latest investment funds the construction of a second drug substance manufacturing site in the Tar Heel state, adding to a previous $550 million commitment.

The new $400 million lab is intended to centralize operations with advanced automation and GMP capabilities.

Rgenta will receive up to $46 million upfront and pre-option milestones, with nearly $500 million per target possible in additional payments.

The sale provides Novavax with a $200 million cash boost and trims $80 million in annual costs.

Five million doses have been secured to address potential H5N1 influenza outbreaks.

The facility will focus on expanding end-to-end insulin production, aiming to address the needs of China’s growing diabetic population.

The biotech transitions to fee-for-service biologics manufacturing to support immunotherapy development.

The facility is capable of manufacturing up to four vaccines or biopharmaceuticals simultaneously.

PTC could earn up to $1.9 billion through development, regulatory, and sales milestones

The PRV was awarded to PTC Therapeutics on November 13, 2024, alongside the approval of Kebilidi for AADC deficiency.

This marks Shorla’s fourth FDA approval.

The acquisition strengthens Roche’s portfolio in allogeneic CAR-T therapies and genetic medicines.

Company shifts focus to other programs after Alzheimer’s trial failure.

The nomination signals a focus on reducing bureaucracy and prioritizing healthcare reforms.

The approval also triggers a $500 million milestone payment to BridgeBio under its royalty funding agreement.

The company cites Evotec's unwillingness to engage in discussions as the deciding factor.

FDA allows trial to continue at reduced dose following rare immune response.

Further expansions include the operational launch of Bio Campus II’s Plant 5 in April 2025.